Background/Aim: Isotretinoin, the drug of choice for severe acne, might be associated with a decrease in insulin sensitivity. Adiponectin is an adipose tissue-derived protein that increases insulin sensitivity. In this study, we aimed to investigate adiponectin levels in postadolescent severe acne and the effect of isotretinoin on adiponectin levels. Methods: Participants included 18 female patients with severe acne and 18 healthy women matched for age and body mass index (BMI). Acne patients completed a 6-month isotretinoin treatment. Anthropometric measurements, serum adiponectin, lipids, fasting glucose, fasting insulin, and homeostatic model assessment for insulin resistance (HOMA-IR) were determined, and a standard 2-h oral glucose tolerance test (OGTT) was performed in healthy women once and in patients with acne before and after treatment. Results: At baseline, patients with acne had significantly lower serum adiponectin levels than controls. Isotretinoin treatment resulted in a significant increase in weight, BMI, and triglyceride and adiponectin levels. Glucose metabolism markers in patients with acne and controls were similar at baseline and did not change after treatment. Baseline OGTT in acne patients revealed an increased adiponectin response at 2 h, which was not present in healthy controls. Remarkably, this OGTT-induced adiponectin increment in acne patients was diminished after isotretinoin treatment. Conclusion: Adiponectin levels are differently regulated in women with severe acne and healthy controls in that circulating basal levels in patients are suppressed and show an increase in response to oral glucose load. Suppression of baseline adiponectin ameliorates after 6 months of isotretinoin treatment, reaching levels similar to those of healthy controls.

Keywords:
Severe acne, Adiponectin, Isotretinoin, Insulin resista
1.
Williams HC, Dellavalle RP, Garner S: Acne vulgaris. Lancet 2012;379:361-372.
2.
Ottaviani M, Camera E, Picardo M: Lipid mediators in acne. Mediators Inflamm 2010;2010:858176.
3.
Del Prete M, Mauriello MC, Faggiano A, Di Somma C, Monfrecola G, Fabbrocini G, Colao A: Insulin resistance and acne: a new risk factor for men? Endocrine 2012;42:555-560.
4.
Peck GL, Olsen TG, Yoder FW, Strauss JS, Downing DT, Pandya M, Butkus D, Arnaud-Battandier J: Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med 1979;300:329-333.
5.
Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, Exner JH: Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol 1984;10:490-496.
6.
Strauss JS, Krowchuk DP, Leyden JJ, Lucky AW, Shalita AR, Siegfried EC, Thiboutot DM, Van Voorhees AS, Beutner KA, Sieck CK, Bhushan R, American Academy of Dermatology/American Academy of Dermatology: Guidelines of care for acne vulgaris management. J Am Acad Dermatol 2007;56:651-663.
7.
Lyons F, Laker MF, Marsden JR, Manuel R, Shuster S: Effect of oral 13-cis-retinoic acid on serum lipids. Br J Dermatol 1982;107:591-595.
8.
Koistinen HA, Remitz A, Gylling H, Miettinen TA, Koivisto VA, Ebeling P: Dyslipidemia and a reversible decrease in insulin sensitivity induced by therapy with 13-cis-retinoic acid. Diabetes Metab Res Rev 2001;17:391-395.
9.
Bonet ML, Ribot J, Felipe F, Palou A: Vitamin A and the regulation of fat reserves. Cell Mol Life Sci 2003;60:1311-1321.
10.
Fantuzzi G: Adiponectin and inflammation: consensus and controversy. J Allergy Clin Immunol 2008;121:326-330.
11.
Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
12.
Kadowaki T, Yamauchi T: Adiponectin and adiponectin receptors. Endocr Rev 2005;26:439-451.
13.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999;257:79-83.
14.
Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946.
15.
Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, Pratley RE, Bogardus C, Tataranni PA: Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. Diabetes 2002;51:1884-1888.
16.
Koistinen HA, Remitz A, Koivisto VA, Ebeling P: Paradoxical rise in serum adiponectin concentration in the face of acid-induced insulin resistance 13-cis-retinoic. Diabetologia 2006;49:383-386.
17.
Heliövaara MK, Remitz A, Reitamo S, Teppo AM, Karonen SL, Ebeling P: 13-cis-retinoic acid therapy induces insulin resistance, regulates inflammatory parameters, and paradoxically increases serum adiponectin concentration. Metabolism 2007;56:786-791.
18.
Cetinozman F, Aksoy DY, Elcin G, Yildiz BO: Insulin sensitivity, androgens and isotretinoin therapy in women with severe acne. J Dermatolog Treat 2014;25:119-122.
19.
Galic S, Oakhill JS, Steinberg GR: Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010;316:129-139.
20.
Corbetta S, Angioni R, Cattaneo A, Beck-Peccoz P, Spada A: Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol 2006;154:83-86.
21.
Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ: Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992;98:895-901.
22.
Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24-30.
23.
Ohashi K, Kihara S, Ouchi N, Kumada M, Fujita K, Hiuge A, Hibuse T, Ryo M, Nishizawa H, Maeda N, Maeda K, Shibata R, Walsh K, Funahashi T, Shimomura I: Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006;47:1108-1116.
24.
Kovacs D, Lovaszi M, Poliska S, Olah A, Biro T, Veres I, Zouboulis CC, Stahle M, Ruhl R, Remenyik E, Torocsik D: Sebocytes differentially express and secrete adipokines. Exp Dermatol 2016;25:194-199.
25.
Jung YR, Lee JH, Sohn KC, Lee Y, Seo YJ, Kim CD, Lee JH, Hong SP, Seo SJ, Kim SJ, Im M: Adiponectin signaling regulates lipid production in human sebocytes. PLoS One 2017;12:e0169824.
26.
Zouboulis CC, Picardo M, Ju Q, Kurokawa I, Torocsik D, Biro T, Schneider MR: Beyond acne: current aspects of sebaceous gland biology and function. Rev Endocr Metab Disord 2016;17:319-334.
27.
Villarroya F, Giralt M, Iglesias R: Retinoids and adipose tissues: metabolism, cell differentiation and gene expression. Int J Obes Relat Metab Disord 1999;23:1-6.
28.
Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999;20:649-688.
29.
Bardot O, Aldridge TC, Latruffe N, Green S: PPAR-RXR heterodimer activates a peroxisome proliferator response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 1993;192:37-45.
30.
Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, Makishima M, Shimomura I: Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003;52:1655-1663.
31.
Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
32.
Osei K, Gaillard T, Schuster D: Plasma adiponectin levels in high risk African-Americans with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes. Obes Res 2005;13:179-185.
33.
Lewandowski KC, Szosland K, O'Callaghan C, Tan BK, Randeva HS, Lewinski A: Adiponectin and resistin serum levels in women with polycystic ovary syndrome during oral glucose tolerance test: a significant reciprocal correlation between adiponectin and resistin independent of insulin resistance indices. Mol Genet Metab 2005;85:61-69.
34.
Unluturk U, Harmanci A, Yildiz BO, Bayraktar M: Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women. Clin Endocrinol 2010;72:469-474.
35.
Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF: Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 2013;98:E388-E396.
36.
Heliövaara MK, Strandberg TE, Karonen SL, Ebeling P: Association of serum adiponectin concentration to lipid and glucose metabolism in healthy humans. Horm Metab Res 2006;38:336-340.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.